Ajanta Pharma Reports Strong Financial Performance Amidst Liquidity Concerns in June 2025 Results
Ajanta Pharma has reported strong financial results for the quarter ending June 2025, achieving its highest quarterly net sales and operating profit in five quarters. Key metrics, including profit before tax and earnings per share, also reached recent peaks, although the company faces challenges with low cash and cash equivalents.
Ajanta Pharma, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results indicate a notable shift in the company's evaluation, with a revision in its score reflecting the positive financial performance observed during this period.The company achieved its highest quarterly net sales in the last five quarters, reaching Rs 1,302.65 crore. This upward trend is mirrored in its operating profit, which also peaked at Rs 351.35 crore. Additionally, profit before tax (PBT) and profit after tax (PAT) reached their highest levels in recent quarters, at Rs 304.80 crore and Rs 255.34 crore, respectively. The earnings per share (EPS) also saw a significant rise, standing at Rs 20.37, indicating enhanced profitability for shareholders.
However, it is important to note that the company's cash and cash equivalents have reached their lowest point in the last six half-yearly periods, suggesting challenges in short-term liquidity.
Overall, Ajanta Pharma's recent financial results highlight a positive trajectory in several key areas, while also pointing to some liquidity concerns.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
